Regeneron (REGN) Tops Q4 EPS by 70c
Get Alerts REGN Hot Sheet
Price: $879.79 -2.95%
Revenue Growth %: +2.2%
Financial Fact:
Total expenses: 857.32M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +2.2%
Financial Fact:
Total expenses: 857.32M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Regeneron (NASDAQ: REGN) reported Q4 EPS of $5.23, $0.70 better than the analyst estimate of $4.53. Revenue for the quarter came in at $1.58 billion versus the consensus estimate of $1.5 billion.
- Fourth quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 14% to $975 million versus fourth quarter 2016 and full year 2017 EYLEA U.S. net sales increased 11% to $3.70 billion versus full year 2016
- Fourth quarter 2017 EYLEA global net sales(1) increased 19% to $1.61 billion versus fourth quarter 2016 and full year 2017 EYLEA global net sales(1) increased 14% to $5.93 billion versus full year 2016
For earnings history and earnings-related data on Regeneron (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
- Tractor Supply (TSCO) Tops Q1 EPS by 12c ; Offers Guidance
- PHINIA Inc. (PHIN) Reports Q1 EPS of $1.08, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!